prasugrel indications/contra

Stem definitionDrug idCAS RN
platelet aggregation inhibitors 4113 150322-43-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • prasugrel
  • prasugrel hydrochloride
  • effient
  • efient
  • prasugrel HCl
  • CS-747
  • LY640315
A piperazine derivative and PLATELET AGGREGATION INHIBITOR that is used to prevent THROMBOSIS in patients with ACUTE CORONARY SYNDROME; UNSTABLE ANGINA and MYOCARDIAL INFARCTION, as well as in those undergoing PERCUTANEOUS CORONARY INTERVENTIONS.
  • Molecular weight: 373.44
  • Formula: C20H20FNO3S
  • CLOGP: 3.43
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 46.61
  • ALOGS: -5.20
  • ROTB: 6

Drug dosage:

DoseUnitRoute
10 mg O

Approvals:

DateAgencyCompanyOrphan
July 10, 2009 FDA ELI LILLY AND CO

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Thrombosis in device 727.28 47.04 126 1805 1632 3382296
Vascular stent stenosis 357.66 47.04 53 1878 220 3383708
Coronary artery restenosis 274.68 47.04 44 1887 331 3383597
Haemorrhage 247.45 47.04 84 1847 19837 3364091
Angina unstable 235.38 47.04 55 1876 3307 3380621
Gastrointestinal haemorrhage 227.13 47.04 83 1848 24291 3359637
Acute myocardial infarction 226.87 47.04 70 1861 12181 3371747
Angina pectoris 221.66 47.04 62 1869 7659 3376269
Myocardial infarction 204.96 47.04 91 1840 44042 3339886
Chest pain 167.59 47.04 77 1854 40198 3343730
Haemorrhage intracranial 135.55 47.04 39 1892 5300 3378628
Epistaxis 118.79 47.04 45 1886 14406 3369522
Device occlusion 117.37 47.04 27 1904 1504 3382424
Cardiac tamponade 101.18 47.04 24 1907 1528 3382400
Vascular pseudoaneurysm 100.62 47.04 20 1911 550 3383378
Upper gastrointestinal haemorrhage 87.01 47.04 26 1905 4017 3379911
Off label use 86.88 47.04 55 1876 53922 3330006
Contusion 85.84 47.04 36 1895 14974 3368954
Haematoma 82.42 47.04 29 1902 7510 3376418
Cerebral haemorrhage 82.03 47.04 31 1900 9823 3374105
Subdural haematoma 79.75 47.04 25 1906 4530 3379398
Thrombosis 77.91 47.04 33 1898 14057 3369871
Subarachnoid haemorrhage 67.24 47.04 20 1911 3036 3380892
Coronary artery thrombosis 65.21 47.04 15 1916 833 3383095
Anaemia 64.82 47.04 46 1885 54287 3329641
Vascular stent thrombosis 62.24 47.04 13 1918 459 3383469
Non-cardiac chest pain 60.28 47.04 15 1916 1165 3382763
Platelet aggregation inhibition 58.56 47.04 8 1923 15 3383913
Coronary artery occlusion 58.41 47.04 18 1913 3077 3380851
Pericardial haemorrhage 56.14 47.04 13 1918 743 3383185

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC B01AC22 BLOOD AND BLOOD FORMING ORGANS
ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
Platelet aggregation inhibitors excl. heparin
MeSH PA D006401 Hematologic Agents
MeSH PA D010975 Platelet Aggregation Inhibitors
CHEBI has role CHEBI:50433 platelet glycoprotein-IIb/IIIa receptor antagonist
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:50266 prodrug
FDA PE N0000008832 Decreased Platelet Aggregation
FDA EPC N0000182142 P2Y12 Platelet Inhibitor
FDA MoA N0000182143 P2Y12 Receptor Antagonists

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Acute coronary syndrome indication 394659003
Percutaneous coronary intervention indication 415070008
Myocardial Reinfarction Prevention indication
Intracranial hemorrhage contraindication 1386000
Acute hemorrhage contraindication 8573003
Acute peptic ulcer with hemorrhage contraindication 12274003
Low blood pressure contraindication 45007003
Hepatic failure contraindication 59927004
Blood coagulation disorder contraindication 64779008 DOID:1247
Aortocoronary artery bypass graft contraindication 67166004
Thrombotic thrombocytopenic purpura contraindication 78129009 DOID:10772
Cerebrovascular accident contraindication 230690007 DOID:6713
Transient ischemic attack contraindication 266257000 DOID:224
Surgical procedure contraindication 387713003
Traumatic injury contraindication 417746004
Significant Bleeding contraindication

Acid dissociation constants calculated using MoKa v3.0.0

scroll-->
Dissociation levelDissociation constantType (acidic/basic)
pKa1 5.53 Basic

Orange Book patent data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 10MG BASE EFFIENT ELI LILLY AND CO N022307 July 10, 2009 RX TABLET ORAL 8404703 Jan. 2, 2023 USE OF PRASUGREL AND ASPIRIN IN PATIENTS REQUIRING THE REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS
EQ 10MG BASE EFFIENT ELI LILLY AND CO N022307 July 10, 2009 RX TABLET ORAL 8569325 Jan. 2, 2023 USE OF PRASUGREL AND ASPIRIN IN PATIENTS REQUIRING THE REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS
EQ 5MG BASE EFFIENT ELI LILLY AND CO N022307 July 10, 2009 RX TABLET ORAL 8404703 Jan. 2, 2023 USE OF PRASUGREL AND ASPIRIN IN PATIENTS REQUIRING THE REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS
EQ 5MG BASE EFFIENT ELI LILLY AND CO N022307 July 10, 2009 RX TABLET ORAL 8569325 Jan. 2, 2023 USE OF PRASUGREL AND ASPIRIN IN PATIENTS REQUIRING THE REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS

Orange Book exclusivity data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 10MG BASE PRASUGREL MYLAN PHARMS INC A205927 July 12, 2017 RX TABLET ORAL Feb. 11, 2018 PATENT CHALLENGE
EQ 5MG BASE PRASUGREL MYLAN PHARMS INC A205927 July 12, 2017 RX TABLET ORAL Feb. 11, 2018 PATENT CHALLENGE
EQ 10MG BASE EFFIENT ELI LILLY AND CO N022307 July 10, 2009 RX TABLET ORAL July 12, 2019 UPDATES TO THE PRODUCT LABELING BASED ON THE RESULTS OF STUDY H7T-MC-TADO TITLED, 'A PHASE 3 DOUBLE-BLIND, RANDOMIZED, MULTICENTER, EFFICACY AND SAFETY STUDY OF PRASUGREL COMPARED TO PLACEBO IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE'
EQ 5MG BASE EFFIENT ELI LILLY AND CO N022307 July 10, 2009 RX TABLET ORAL July 12, 2019 UPDATES TO THE PRODUCT LABELING BASED ON THE RESULTS OF STUDY H7T-MC-TADO TITLED, 'A PHASE 3 DOUBLE-BLIND, RANDOMIZED, MULTICENTER, EFFICACY AND SAFETY STUDY OF PRASUGREL COMPARED TO PLACEBO IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE'
EQ 10MG BASE EFFIENT ELI LILLY AND CO N022307 July 10, 2009 RX TABLET ORAL Jan. 12, 2020 PEDIATRIC EXCLUSIVITY
EQ 5MG BASE EFFIENT ELI LILLY AND CO N022307 July 10, 2009 RX TABLET ORAL Jan. 12, 2020 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
P2Y purinoceptor 12 GPCR ANTAGONIST UNKNOWN CHEMBL

External reference:

scroll-->
IDSource
4029056 VUID
N0000179815 NUI
C1620287 UMLSCUI
7562 IUPHAR_LIGAND_ID
D05597 KEGG_DRUG
34K66TBT99 UNII
8503 INN_ID
613391 RXNORM
26287 MMSL
d07409 MMSL
4029056 VANDF
443129001 SNOMEDCT_US
443312008 SNOMEDCT_US
N0000179815 NDFRT
012994 NDDF
6918456 PUBCHEM_CID
CHEMBL1201772 ChEMBL_ID
CHEMBL1201773 ChEMBL_ID
DB06209 DRUGBANK_ID
389574-19-0 SECONDARY_CAS_RN
D000068799 MESH_DESCRIPTOR_UI
CHEBI:87715 CHEBI

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
Effient HUMAN PRESCRIPTION DRUG LABEL 1 0002-5121 TABLET, FILM COATED 5 mg ORAL NDA 19 sections
Effient HUMAN PRESCRIPTION DRUG LABEL 1 0002-5123 TABLET, FILM COATED 10 mg ORAL NDA 19 sections
Prasugrel HUMAN PRESCRIPTION DRUG LABEL 1 0378-5185 TABLET, FILM COATED 5 mg ORAL ANDA 19 sections
Prasugrel HUMAN PRESCRIPTION DRUG LABEL 1 0378-5186 TABLET, FILM COATED 10 mg ORAL ANDA 19 sections
Prasugrel HUMAN PRESCRIPTION DRUG LABEL 1 43817-239 TABLET, FILM COATED 5 mg ORAL ANDA 19 sections
Prasugrel HUMAN PRESCRIPTION DRUG LABEL 1 43817-240 TABLET, FILM COATED 10 mg ORAL ANDA 19 sections
Effient HUMAN PRESCRIPTION DRUG LABEL 1 54868-6238 TABLET, FILM COATED 10 mg ORAL NDA 20 sections
Effient HUMAN PRESCRIPTION DRUG LABEL 1 55154-1831 TABLET, FILM COATED 10 mg ORAL NDA 19 sections
Prasugrel HUMAN PRESCRIPTION DRUG LABEL 1 60505-4642 TABLET, FILM COATED 5 mg ORAL ANDA 19 sections
Prasugrel HUMAN PRESCRIPTION DRUG LABEL 1 60505-4643 TABLET, FILM COATED 10 mg ORAL ANDA 19 sections
Prasugrel HUMAN PRESCRIPTION DRUG LABEL 1 65862-829 TABLET, FILM COATED 5 mg ORAL ANDA 19 sections
Prasugrel HUMAN PRESCRIPTION DRUG LABEL 1 65862-830 TABLET, FILM COATED 10 mg ORAL ANDA 19 sections
Prasugrel HUMAN PRESCRIPTION DRUG LABEL 1 66993-575 TABLET, FILM COATED 5 mg ORAL NDA authorized generic 19 sections
Prasugrel HUMAN PRESCRIPTION DRUG LABEL 1 66993-576 TABLET, FILM COATED 10 mg ORAL NDA authorized generic 19 sections
PRASUGREL HUMAN PRESCRIPTION DRUG LABEL 1 67877-604 TABLET, FILM COATED 5 mg ORAL ANDA 19 sections
PRASUGREL HUMAN PRESCRIPTION DRUG LABEL 1 67877-605 TABLET, FILM COATED 10 mg ORAL ANDA 19 sections